- Home
- ACIU vs NECB Comparison
ACIU vs NECB Comparison
Compare ACIU & NECB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- NECB
- Stock Information
- Founded
- ACIU 2003
- NECB 1934
- Country
- ACIU Switzerland
- NECB United States
- Employees
- ACIU N/A
- NECB N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- NECB Savings Institutions
- Sector
- ACIU Health Care
- NECB Finance
- Exchange
- ACIU Nasdaq
- NECB Nasdaq
- Market Cap
- ACIU 247.4M
- NECB 295.3M
- IPO Year
- ACIU 2016
- NECB N/A
- Fundamental
- Price
- ACIU $1.88
- NECB $23.83
- Analyst Decision
- ACIU Strong Buy
- NECB
- Analyst Count
- ACIU 2
- NECB 0
- Target Price
- ACIU $12.00
- NECB N/A
- AVG Volume (30 Days)
- ACIU 187.3K
- NECB 57.2K
- Earning Date
- ACIU 03-13-2025
- NECB 04-24-2025
- Dividend Yield
- ACIU N/A
- NECB 3.17%
- EPS Growth
- ACIU N/A
- NECB 6.02
- EPS
- ACIU N/A
- NECB 3.52
- Revenue
- ACIU $30,136,397.00
- NECB $104,835,000.00
- Revenue This Year
- ACIU $120.91
- NECB $2.80
- Revenue Next Year
- ACIU $13.82
- NECB $8.34
- P/E Ratio
- ACIU N/A
- NECB $6.73
- Revenue Growth
- ACIU 84.51
- NECB 5.02
- 52 Week Low
- ACIU $1.77
- NECB $14.84
- 52 Week High
- ACIU $4.98
- NECB $31.72
- Technical
- Relative Strength Index (RSI)
- ACIU 29.21
- NECB 57.13
- Support Level
- ACIU $1.77
- NECB $22.71
- Resistance Level
- ACIU $2.05
- NECB $23.80
- Average True Range (ATR)
- ACIU 0.12
- NECB 0.66
- MACD
- ACIU -0.02
- NECB 0.16
- Stochastic Oscillator
- ACIU 18.71
- NECB 97.18
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About NECB NorthEast Community Bancorp Inc.
NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. They conduct their activities throughout the Northeastern United States including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.